Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.

Journal of cardiovascular pharmacology - 1 May 2021

Benbrahim Meissane, Norman Kelsey, Sanchorawala Vaishali, Siddiqi Omar K, Hughes David

Abstract excerpt

ABSTRACT: Transthyretin (ATTR) amyloidosis is a multisystem disease caused by organ deposition of amyloid fibrils derived from the misfolded transthyretin (TTR) protein. The purpose of this article is to provide an overview of current treatment regimens and summarize important considerations for each agent. A literature search was performed with the PubMed database for articles published through October 2020....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid Neuropathies, Familial
Share to Cardiomyopathies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cardiovascular Agents

Share to Genetic Predisposition to Disease

Share to Oligonucleotides

Share to Prealbumin

Share to RNA, Small Interfering

Share to Treatment Outcome

Source

Identifiers

PMID: 33657048
DOI: 10.1097/FJC.0000000000001004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.PMID 33657048Read ↗

Transthyretin Amyloid Cardiomyopathy–2025 Update: Current Diagnostic Approaches and Emerging Therapeutic OptionsSemantic proximity Read ↗

Transthyretin Amyloid Cardiomyopathy Treatment: An Updated ReviewSemantic proximity Read ↗

Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trialsSemantic proximity Read ↗

Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope.Semantic proximity Read ↗

[Recommendations update for the diagnosis and treatment of transthyretin variant amyloidosis (ATTRv)].Semantic proximity Read ↗

Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort studySemantic proximity Read ↗

Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort studySemantic proximity Read ↗

Novel drugs targeting transthyretin amyloidosis.Semantic proximity Read ↗

Impact of RNAi therapeutics on cardiac parameters in patients with hereditary transthyretin amyloidosis initially treated with stabilizers: A French real-world study.Semantic proximity Read ↗

The transthyretin amyloidoses: advances in therapySemantic proximity Read ↗

Emerging, novel gene-modulating therapies for transthyretin amyloid cardiomyopathySemantic proximity Read ↗

Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.